about
Post-Genomics and Vaccine Improvement for LeishmaniaEx vivo host and parasite response to antileishmanial drugs and immunomodulatorsBrazilian Amazon Traditional Medicine and the Treatment of Difficult to Heal Leishmaniasis Wounds with CopaiferaImmune regulation during chronic visceral leishmaniasis.Role of protein kinase R in the killing of Leishmania major by macrophages in response to neutrophil elastase and TLR4 via TNFα and IFNβ.NK cell activity differs between patients with localized and diffuse cutaneous leishmaniasis infected with Leishmania mexicana: a comparative study of TLRs and cytokines.Development of a novel formulation with hypericin to treat cutaneous leishmaniasis based on photodynamic therapy in in vitro and in vivo studies.Real-time PCR assay for detection and quantification of Leishmania (Viannia) organisms in skin and mucosal lesions: exploratory study of parasite load and clinical parameters.Deletion of Wiskott-Aldrich syndrome protein triggers Rac2 activity and increased cross-presentation by dendritic cells.Characterization of the Histopathologic Features in Patients in the Early and Late Phases of Cutaneous Leishmaniasis.Three Leishmania/L. species--L. infantum, L. major, L. tropica--as causative agents of mucosal leishmaniasis in Iran.Psychosocial impact of scars due to cutaneous leishmaniasis on high school students in Errachidia province, Morocco.Nanoparticles as multifunctional devices for the topical treatment of cutaneous leishmaniasis.Neurological disease in human and canine leishmaniasis--clinical features and immunopathogenesis.Annexin A1 Is Involved in the Resolution of Inflammatory Responses during Leishmania braziliensis Infection.Leishmania infection: painful or painless?Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review.Gene deleted live attenuated Leishmania vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response in human PBMCs.Activity of synthetic chalcones in hamsters experimentally infected with Leishmania (Viannia) braziliensis.Proteome profiling of human cutaneous leishmaniasis lesion.Mucosal leishmaniasis mimicking T-cell lymphoma in a patient receiving monoclonal antibody against TNFα.Reactivation of cutaneous and mucocutaneous tegumentary leishmaniasis in rheumatoid arthritis patients: an emerging problem?Human Neutrophil Peptide 1 as immunotherapeutic agent against Leishmania infected BALB/c mice.Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis.STAT6 Mediates Footpad Immunopathology in the Absence of IL-12p40 Following Infection of Susceptible BALB/c Mice With Leishmania major.The Binomial Parasite-Host Immunity in the Healing Process and in Reactivation of Human Tegumentary Leishmaniasis.Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome and AmBisome in murine cutaneous leishmaniasisTransforming Growth Factor Beta (TGFβ1) and Epidermal Growth Factor (EGF) as Biomarkers of Infection and Early Therapeutic Response in Cutaneous Leishmaniasis: Studies in HamstersLocal Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B
P2860
Q26752532-6CCB50D4-9F45-479B-8D41-836172524D6FQ28547648-5F69FDB2-222A-4CA7-899F-B918EE668F7AQ28817860-3AD462CA-F842-4CA9-9153-CDE5C5B6AAB1Q33881718-EFA5644C-F532-4427-BA5F-151A572CF192Q34409712-2773000D-248A-4866-A1DF-A7A6DDA54A01Q34513470-A65E9B2C-F2F4-4253-9690-9CC137967AFEQ35960805-E9FD28AD-EA9C-4B8E-9995-A19B97417905Q37026407-35343BE0-440A-4999-8F91-18E61A91746DQ37124582-45698449-7FBD-44E6-9E8D-36309488E914Q37715361-13906881-94B3-4E0B-8D7A-7AAB0314FC9AQ37726447-33026693-D01C-464E-AE37-6D904259A94EQ37740950-79AF8C1A-DC0E-4333-A892-246E27AD0350Q38195310-A25C2DF5-875C-4707-BB5D-5FC18339AE7AQ38486593-8A4F448C-594C-46FA-B424-0F980EB3028EQ38910414-FF792714-4D22-4480-A6C4-D59583FDCAB5Q38915271-1880367A-0B7A-4688-865B-46FA70B45B08Q38962452-BD97BE39-36F7-42B9-9EDA-78D5CC504AA7Q40541534-0E676E25-4B95-4591-A590-B7279CD57B08Q41147459-D9F2EA68-BD25-4035-8D03-DAAC20421D69Q41744907-5DD2696A-DCBC-46B3-9646-EEF3C2909FB0Q41995657-BAFC858F-2559-491D-856F-D4E36E58C9F1Q42347671-A0FC9ABA-E4D8-4801-8DCD-0908767F8597Q47775690-062BCC09-B45E-47EE-8BE2-B123D016A309Q51771412-BEFA5C77-BA93-40A6-88DF-F786D4D811E6Q55024938-33476FEC-D63E-4D2B-AE75-A9E450FF1FF8Q55408705-FDC8E77D-917E-4E7A-BABF-2776FEEC5EB3Q57952724-3A9CF85D-3BE7-4A6C-A9E1-EBDADB5B76D0Q58586136-F67717BC-DB34-42C6-8BE7-2A0DC2A6A7B3Q58701149-82FF5F0D-1752-494B-83FC-18C9925C65EC
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Tissue damage and immunity in cutaneous leishmaniasis.
@en
type
label
Tissue damage and immunity in cutaneous leishmaniasis.
@en
prefLabel
Tissue damage and immunity in cutaneous leishmaniasis.
@en
P356
P1433
P1476
Tissue damage and immunity in cutaneous leishmaniasis.
@en
P304
P356
10.1111/PIM.12007
P577
2012-12-01T00:00:00Z